01 September 2003
Bone marrow supression and acute renal failure related to single dose of 500 miligram dipyrone
Kürsad Erinc , Murat Aslan , Filiz Aslan , Cengiz Beyan , Ertan Demirtas FaccCase Rep Clin Pract Rev 2003; 4(2):94-96 :: ID: 429041
Abstract
Background: Nonsteroid anti-inflammatory drugs may cause idiosyncrasy in some susceptible individuals. This case is presented in order to make an impact on a rare form of dipyrone-associated idiosyncrasy.Case Report: A 68-year-old female was hospitalized with dyspnea, pretibial edema and fatigue. Initial complete blood count, hepatic and renal functions were normal. On 4th day of her hospitalization, she was given 500 mg dipyrone because she suffered toothache. In the following days, moderate decrement of the blood cells (WBC: 2.0i103/KL, RBC: 3.00i106/KL, Hb: 9.2 g/dl, Htc: 28%, Platelets: 82i103/KL) and further abnormality of renal function (BUN: 124 mg/dl, creatinine: 7.0 mg/dl) were encountered. On 9th day, renal functions were normal (BUN: 35 mg/dl, creatinine: 0.9 mg/dl). At that time, complete blood count values were as follows: Hb: 9.8 g/dl, Htc: 30.3%, WBC: 5.1i103/KL, Platelets: 237i103/KL. Conclusions: Dipyrone-associated idiosyncrasy may result serious abnormalities in renal and hemopoetic functions. Therefore, using dipyrone must require attention in certain situations.
Keywords: bone marrow suppression, Dipyrone, Idiosyncrasy
1,006
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.953653
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.952921
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.953836
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.953506
Most Viewed Current Articles
07 Dec 2021 : Case report
22,773,072
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
179,002
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
122,896
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
67,375
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






